RELATED STUDY
Persistent Diarrhea and Eosinophilic Esophagitis Resulting From Chronic Cannabidiol Usage for Refractory Epilepsy
Key Findings: This case report presents a young patient with treatment-resistant epilepsy on cannabidiol (CBD) who presented with diarrhea, vomiting, and abdominal pain and distention lasting several weeks. Symptoms resolved after a reduction in the dose of the CBD compound.
Type of Study: Meta-analysis
Study Sample Size: 1
Study Result: Negative
Study Location(s): United States
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC)
Phytocannabinoid Source: Cannabis Flower derived
Chemotype: Chemotype III
Receptors Studied: CB1, CB2, TRPV1
DOSING DETAILS 
Study Dosing Objective: Other
Established Protocol: Adverse effects
Route of Administration: Oral (Ingestion)
Cannabinoid Ratio: (CBD) 0 
Dosing Regimen: CBD 10 mg/kg/day
Starting Dose: 20 mg/kg/day
Titration: A gradual decrease of the cannabidiol from 20 mg/kg/day (450 mg BID) to 15 mg/kg/day (350 mg BID)
Clinical Relevance: A case report of a patient on long-term cannabidiol therapy with persistent diarrhea, abdominal pain, weight loss, and esophageal eosinophilia likely due to cannabidiol. Symptoms improved with dose adjustments over 2 weeks.
Adverse Events: persistent diarrhea, abdominal pain, peripheral eosinophilia, esophageal eosinophilia, and weight loss
Additional Notes: Dose Titration
Link to study
